Neurelis

Neurelis

Specialty pharmaceutical firm that licenses, develops, and commercializes product candidates for epilepsy and the cns market.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor investor investor

€0.0

round

$150m

Debt
Total Funding000k
More about Neurelis
Made with AI
Edit

Neurelis, Inc. is a neuroscience-based pharmaceutical company focused on delivering innovative therapies designed to address unmet medical needs. The company operates in the pharmaceutical and biotechnology market, serving patients and healthcare professionals (HCPs) with a range of proprietary technologies aimed at enhancing drug delivery and stabilization. Neurelis' business model revolves around the development and commercialization of novel therapeutic solutions, leveraging its proprietary non-invasive drug delivery technologies to improve clinical outcomes and patient care. The company generates revenue through the sale of its pharmaceutical products and through partnerships and collaborations with other entities in the healthcare sector. Neurelis is committed to advancing its pipeline of investigational product candidates, which are at various stages of development, to bring new and effective treatments to market.

Keywords: neuroscience, pharmaceutical, innovative therapies, drug delivery, patient care, proprietary technologies, biotechnology, healthcare professionals, clinical outcomes, investigational products.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Neurelis

Edit
Aegis Therapeutics
ACQUISITION by Neurelis Dec 2018